Recombinant erythropoietin and chronic renal failure.
The hormone deficiency that underlies anemia in chronic kidney failure can now be corrected. Along with the primary benefit of raising the hematocrit and reversing anemia, dramatic secondary benefits can be achieved. Exercise capacity, neuropsychiatric and sexual function, and overall quality of life are enhanced. Guidelines for management are discussed.
Lundin
A P
AP
State University of New York, Brooklyn.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000096:biosynthesis / Q000172:deficiency / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects
D011994:Recombinant Proteins; D004921:Erythropoietin